Microbix Biosystems Inc represents the values of exceptional innovation, dedication to quality, and commitment to customer satisfaction. As a leading biotechnology company, Microbix is driven by a strong corporate philosophy centered on advancing human health through the development and production of high-quality diagnostic reagents and viral antigens. With a focus on continuous improvement, Microbix strives to deliver superior products and services to meet the evolving needs of the healthcare industry. By prioritizing research and development, along with stringent quality control measures, Microbix Biosystems Inc ensures its reputation as a trusted provider of essential biological products.

Microbix Biosystems Inc is primarily present in Canada, United States, Europe, and Asia.

Microbix Biosystems Inc, a leading life science company, has accomplished several significant milestones. Notably, the company successfully developed and launched key products in the virology industry, including Quality Assessment (QA) controls for viral diseases and viral antigens. Microbix Biosystems Inc also introduced innovative technologies like the Kinlytic Urokinase, a clot-dissolving agent. Through strategic partnerships, the company expanded its global presence and garnered recognition for its exceptional research and development capabilities. Furthermore, Microbix Biosystems Inc achieved ISO 13485 certification, validating its commitment to quality management systems. These achievements solidify the company's position as a prominent player in the biotechnology sector.

Microbix Biosystems Inc is a well-established company with a rich history and background. Founded in 1988, Microbix has grown to become a leading provider of biological products and technologies worldwide. The company specializes in the development, manufacture, and distribution of biological materials used in the diagnostics, research, and quality control fields. With its state-of-the-art facilities and dedicated team of experts, Microbix has consistently delivered innovative solutions to the global life sciences industry. Their wide range of products and services includes viral antigens, quality assessment programs, and proficiency panels. Throughout its history, Microbix Biosystems Inc has remained committed to providing high-quality products and contributing to advancements in the healthcare sector.

The main competitors of Microbix Biosystems Inc in the market include companies such as Becton, Dickinson and Company (BD), Bio-Rad Laboratories, and Meridian Bioscience Inc.

Microbix Biosystems Inc is primarily active in the fields of virology and molecular diagnostics.

Microbix Biosystems Inc is a leading biotechnology company with a robust business model focused on developing and commercializing innovative biological products. The company specializes in producing and marketing unique biological substances, such as antigens and quality assessment controls, for diagnostic testing and scientific research. Microbix Biosystems Inc leverages its extensive expertise in virology, immunology, and bioprocessing to provide high-quality products to diagnostic laboratories, biopharmaceutical companies, and research institutions worldwide. With a continued commitment to advancing healthcare and scientific research, Microbix Biosystems Inc has established a strong reputation as a trusted partner in the industry.

Microbix Biosystems KGV ir 18,77.

Microbix Biosystems KUV ir 2,03.

AlleAktien kvalitātes vērtējums Microbix Biosystems ir 5/10.

gaidāmā Microbix Biosystems apgrozījums ir 25,45 milj. CAD.

gaidāmā Microbix Biosystems peļņa ir 2,76 milj. CAD.

Microbix Biosystems Inc is a Toronto-based biotechnology company that focuses on researching, developing, and marketing diagnostic and therapeutic products. The company operates in three business areas: Diagnostic test systems, infectious diseases, and bioproducts.

Microbix Biosystems izmaksā dividendes 0 CAD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Microbix Biosystems vai uzņēmums nedod dividendes.

Microbix Biosystems ISIN ir CA59501P1045.

Microbix Biosystems WKN ir 935162.

Microbix Biosystems simbols ir MBX.TO.

Pēdējo 12 mēnešu laikā Microbix Biosystems maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Microbix Biosystems plāno maksāt dividendes 0 CAD apmērā.

Microbix Biosystems pašreizējā dividendu rentabilitāte ir .

Microbix Biosystems maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Microbix Biosystems pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CAD. Tas atbilst dividendes ražībai 0 %.

Microbix Biosystems tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Microbix Biosystems apmērā 0 CAD, kas tika izmaksāta 7.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.09.2024..

Pēdējās dividendes izmaksa notika 7.09.2024..

Gadā 2023, Microbix Biosystems izmaksāja 0 CAD dividendes.

Microbix Biosystems dividendes tiek izmaksātas CAD.